Cohance Lifesciences Limited
COHANCE.BO
Bombay Stock Exchange424.70
INR
-3.55
- -
Cohance Lifesciences Limited
COHANCE.BO
(Bombay Stock Exchange)
Recent
price
424.70
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Cohance Lifesciences Limited (COHANCE.BO) is an integrated, technology-driven global contract development and manufacturing organization (CDMO) that supports pharmaceutical, biotechnology, and fine chemical companies in developing and manufacturing new chemical entities (NCEs), active pharmaceutical ingredients (APIs), intermediates, and formulations. The company offers comprehensive services including custom synthesis; process research and development; scale-up and validation; clinical and commercial contract manufacturing of APIs, high-potent APIs, pharmaceutical formulation intermediates, and specialty chemicals; antibody-drug conjugate (ADC) payloads, linkers, and bioconjugation; high-purity oligonucleotide building blocks, modified nucleosides, and locked nucleic acids; analytical services; regulatory support; and supply chain management. It operates eight manufacturing units, five of which are USFDA-approved, along with two dedicated R&D centers focused on complex molecule development, nucleic acid chemistry, oncology, and green chemistry processes; the company serves innovator and generic markets globally with core competencies in cyanation, heterocyclic chemistry (pyrimidines, quinolones, thiazoles, imidazoles), and customized solutions for challenging development needs. Founded in 1989 and headquartered in Hyderabad, India, Cohance Lifesciences maintains a strong presence in India through multiple facilities in Hyderabad and a global footprint including its US-based subsidiary NJ Bio Inc. in New Jersey, which enhances capabilities in bioconjugation and ADC technologies. The company, publicly traded on the Bombay Stock Exchange, caters to leading life science firms with an emphasis on quality assurance, GMP-compliant production, and end-to-end support from early-stage R&D to commercial supply. In recent developments, Cohance Lifesciences, formerly Suven Pharmaceuticals Limited, completed a strategic merger with Cohance Life Sciences effective May 1, 2025, following approval from India's Department of Pharmaceuticals; the merged entity adopted the Cohance Lifesciences name on May 7, 2025, combining Suven's commercial scale with expertise in ADCs, oligonucleotides, and complex chemistry to target ₹8,500 crore in annual revenue. The company acquired a majority 56% stake in NJ Bio Inc. through a $64.4 million transaction in early 2025, bolstering its ADC platform. In August 2025, it announced a $10 million (approximately Rs 87 crore) investment in NJ Bio to expand cGMP bioconjugation capabilities and Rs 23-230 million in a new Hyderabad facility for oligonucleotide building block manufacturing (up to 700 kg annual GMP capacity), with validations underway and customer audits planned; these expansions support high-growth modalities like oligonucleotides and ADCs amid organizational upgrades.